High Risk Neuroblastoma Study 2 (HR-NBL2)


Trial overview and summary

High Risk Neuroblastoma Study 2: A randomized, international and multicentric phase 3 study that evaluates and compares 2 treatment strategies in 3 therapeutic phases (induction, high-dose chemotherapy and radiotherapy) for patients with high-risk neuroblastoma.

Patients with high-risk neuroblastoma (HR-NBL) are currently offered multimodal treatment including induction chemotherapy, high-dose chemotherapy (HDC) followed by autologous stem cell rescue (ASCR), local treatment (surgery and radiotherapy) and maintenance treatment. Despite all these treatments, the outcome often remains poor.

In HR-NBL2, we look to define the most effective threatment at each stage by comparing 2 therapies offered at 3 separate randomisation steps: at induction (RAPID COJEC (SIOPEN) vs N5-N6 regimens), at HDC (single HDC vs tandem HDC+Thiotepa), and at local radiotherapy (standard dose vs an increased radiotherapy dose).

Chief Investigator

Dr Dominique Valteau Couanet

Gustave Roussy (Villejuif, France)

UK Lead Investigator

Dr Martin Elliott

Leeds Children’s Hospital

More information